PSD-95: An Effective Target for Stroke Therapy Using Neuroprotective Peptides
Round 1
Reviewer 1 Report
The second leading cause of death in the world is stroke. Therefore, finding new effective therapies or improving existing therapies for stroke is one of the main challenges of many laboratories around the world. One potential therapy for stroke is the use of neuroprotective peptides. In this review, the authors focus on the latest literature reports on three CPP conjugates (fragment 47-57 of Tat peptide) - nerinetide (phase 3 clinical trials), AVLX-144 (phase 1 clinical trials) and TP95414 - targeted at the postsynaptic density protein (PSD-95), which plays a major role in the mechanism of neuronal death after ischemic stroke. In my opinion, the manuscript is well written, the subject of the work is up-to-date and consistent with the title of the special issue, it is a very valuable source of information both on the neuronal death mechanisms in which PSD-95 participates and the recent advances in the development of therapy based on CPPs targeting PSD-95.
Reviewer 2 Report
A well-written review article on the use of Tat peptide derivatives against PSD-95. It is a valuable contribution to the research on the use of peptides as neuroprotective compounds. I am glad that the authors mentioned that CPP peptides are used not only as carriers, but also have neuroprotective properties by themselves. I recommend the article for publication. The only defect that I noticed is: p11 l 442 : there is: ... and TP95 259 (double typed the same label) it should be: ... and TP95 414.
